Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,645

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Contribution of platelets to tumour metastasis

Open access
Gay, Laurie J., Felding-Habermann, Brunhilde·2011·Nature Reviews Cancer
DOI 10.1038/nrc3004
Open this paper in CoChat — free account

Abstract

Extensive experimental evidence shows that platelets support tumour metastasis. The activation of platelets and the coagulation system have a crucial role in the progression of cancer. Within the circulatory system, platelets guard tumour cells from immune elimination and promote their arrest at the endothelium, supporting the establishment of secondary lesions. These contributions of platelets to tumour cell survival and spread suggest platelets as a new avenue for therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc3004

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 163

  1. Khorana, A. A. & Connolly, G. C. Assessing risk of venous thromboembolism in the patient with cancer. J. Clin. Oncol. 27, 4839–4847 (2009). · DOI
  2. Lyman, G. H. & Khorana, A. A. Cancer, clots and consensus: new understanding of an old problem. J. Clin. Oncol. 27, 4821–4826 (2009). · DOI
  3. Khorana, A. A. & Fine, R. L. Pancreatic cancer and thromboembolic disease. Lancet Oncol. 5, 655–663 (2004). · DOI · Paper page
  4. Lugassy, G., Falanga, A., Kakkar, A. & Rickles, F. Thrombosis and Cancer (Informa Health Care, London, 2004). · DOI
  5. Trousseau, A. in Clinique Medicale de l'Hotel-Dieu de Paris 2nd ed (ed. Bailliere, J. B. ) Vol. 3, 654–712 (Paris,1865).
  6. Khorana, A. A. Malignancy, thrombosis and Trousseau: the case for an eponym. J. Thromb. Haemost. 1, 2463–2465 (2003). · DOI
  7. Sierko, E. & Wojtukiewicz, M. Z. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin. Thromb. Hemost. 33, 712–721 (2007). · DOI
  8. Sierko, E. & Wojtukiewicz, M. Z. Platelets and angiogenesis in malignancy. Semin. Thromb. Hemost. 30, 95–108 (2004). · DOI · Paper page
  9. Prisco, D. et al. Platelet activation and platelet lipid composition in pulmonary cancer Prostaglandins Leukot. Essent. Fatty Acids 53, 65–68 (1995). · DOI
  10. Blann, A. D. et al. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul. Fibrinolysis 12, 43–50 (2001). · DOI
  11. Verheul, H. M. W. et al. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin. Cancer Res. 6, 166–171 (2000).
  12. Erdemir, F. et al. Clinical significance of platelet count in patients with renal cell carcinoma. Urol. Int. 79, 111–116 (2007). · DOI
  13. Costantini, V., Zacharski, L. R., Moritz, T. E. & Edwards, R. L. The platelet count in carcinoma of the lung and colon. Thromb. Haemost. 64, 501–505 (1990). · DOI
  14. Ayhan, A. et al. The value of preoperative platelet count in the prediction of cervical involvement and poor prognostic variables in patients with endometrial carcinoma. Gynecol. Oncol. 103, 902–905 (2006). · DOI
  15. Taucher, S. et al. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb. Haemost. 89, 1098–1106 (2003). · DOI
  16. Brown, K. M., Domin, C., Aranha, G. V., Yong, S. & Shoup, M. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am. J. Surg. 189, 278–282 (2005). · DOI
  17. Bensalah, K. et al. Prognostic value of thrombocytosis in renal cell carcinoma. J. Urol. 175, 859–863 (2006). · DOI
  18. Brockmann, M. A. et al. Preoperative thrombocytosis predicts poor survival in patients with glioblastoma. Neuro-Oncology 9, 335–342 (2007). · DOI
  19. Kaushansky, K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 111, 981–986 (2008). · DOI · Paper page
  20. Ruggeri, Z. M. & Mendolicchio, G. L. Adhesion mechanisms in platelet function. Circ. Res. 100, 1673–1685 (2007). · DOI · Paper page
  21. Kakkar, A. K., Deruvo, N., Chinswangwatanakul, V., Tebbutt, S. & Williamson, R. C. N. Extrinsic-pathway activation in cancer with high factor VIIA and tissue factor. Lancet 346, 1004–1005 (1995). · DOI
  22. Mueller, B. M., Reisfeld, R. A., Edgington, T. S. & Ruf, W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc. Natl Acad. Sci. USA 89, 11832–11836 (1992). · DOI · Paper page
  23. Ruf, W. & Mueller, B. M. Thrombin generation and the pathogenesis of cancer. Semin. Thromb. Hemost. 32, 061, 068 (2006). · DOI
  24. Esumi, N., Fan, D. & Fidler, I. J. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res. 51, 4549–4556 (1991).
  25. Nierodzik, M. L., Plotkin, A., Kajumo, F. & Karpatkin, S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J. Clin. Invest. 87, 229–236 (1991). · DOI
  26. Hu, L., Lee, M., Campbell, W., Perez-Soler, R. & Karpatkin, S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 104, 2746–2751 (2004). · DOI
  27. Nierodzik, M. L. & Karpatkin, S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10, 355–362 (2006). · DOI · Paper page
  28. Ruf, W. Tissue factor and PAR signaling in tumor progression. Thromb. Res. 120, S7–S12 (2007). · DOI
  29. Ruf, W., Yokota, N. & Schaffner, F. Tissue factor in cancer progression and angiogenesis. Thromb. Res. 125, S36–S38 (2010). · DOI
  30. Gupta, G. P. & Massague, J. Cancer metastasis: Building a framework. Cell 127, 679–695 (2006). · DOI · Paper page
  31. Nguyen, D. X., Bos, P. D. & Massague, J. Metastasis: from dissemination to organ-specific colonization. Nature Rev. Cancer 9, 274–284 (2009). · DOI · Paper page
  32. Psaila, B. & Lyden, D. The metastatic niche: adapting the foreign soil. Nature Rev. Cancer 9, 285–293 (2009). · DOI · Paper page
  33. Steeg, P. S. Tumor metastasis: mechanistic insights and clinical challenges. Nature Med. 12, 895–904 (2006). · DOI
  34. Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nature Rev. Cancer 2, 563–572 (2002). · DOI · Paper page
  35. Honn, K. V., Tang, D. G. & Chen, Y. Q. Platelets and cancer metastasis-more than an epiphenomenon. Semin. Thromb. Hemost. 18, 392–415 (1992). · DOI
  36. Mehta, P. Potential role of platelets in the pathogenesis of tumor-metastasis. Blood 63, 55–63 (1984). · DOI
  37. Jurasz, P., Alonso-Escolano, D. & Radomski, M. W. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br. J. Pharmacol. 143, 819–826 (2004).
  38. Erpenbeck, L. & Schon, M. P. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 115, 3427–3436 (2010). · DOI · Paper page
  39. Mohle, R., Green, D., Moore, M., Nachman, R. & Rafii, S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl Acad. Sci. USA 94, 663–668 (1997). · DOI · Paper page
  40. Pinedo, H. M., Verheul, H. M. W., D'Amato, R. J. & Folkman, J. Involvement of platelets in tumour angiogenesis? The Lancet 352, 1775–1777 (1998). · DOI · Paper page
  41. Coppinger, J. A. et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 103, 2096–2104 (2004). · DOI · Paper page
  42. Smyth, S. S. et al. Platelet functions beyond hemostasis. J. Thromb. Haemost. 7, 1759–1766 (2009). · DOI · Paper page
  43. Brock, T. A., Dvorak, H. F. & Senger, D. R. Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am. J. Pathol. 138, 213–221 (1991).
  44. Jin, D. K. et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nature Med. 12, 557–567 (2006). · DOI · Paper page
  45. Ma, L. et al. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc. Natl Acad. Sci. USA 102, 216–220 (2005). · DOI · Paper page
  46. Italiano, J. E. Jr et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet α granules and differentially released. Blood 111, 1227–1233 (2008). · DOI · Paper page
  47. Boucharaba, A. et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest. 114, 1714–1725 (2004). · DOI · Paper page
  48. Kim, Y. J., Borsig, L., Varki, N. M. & Varki, A. P-selectin deficiency attenuates tumor growth and metastasis. Proc. Natl Acad. Sci. USA 95, 9325–9330 (1998). · DOI · Paper page
  49. Zaslavsky, A. et al. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 115, 4605–4613 (2010). · DOI
  50. Palumbo, J. S. et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105, 178–185 (2005). · DOI · Paper page
  51. Palumbo, J. S. et al. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 62, 6966–6972 (2002).
  52. Jain, S., Russell, S. & Ware, J. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. J. Thromb. Haemost. 7, 1713–1717 (2009). · DOI
  53. Ho-Tin-Noe, B., Goerge, T., Cifuni, S. M., Duerschmied, D. & Wagner, D. D. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res. 68, 6851–6858 (2008). · DOI
  54. Ho-Tin-Noe, B. et al. Innate immune cells induce hemorrhage in tumors during thrombocytopenia. Am. J. Pathol. 175, 1699–1708 (2009). · DOI
  55. Ho-Tin-Noe, B., Goerge, T. & Wagner, D. D. Platelets: guardians of tumor vasculature. Cancer Res. 69, 5623–5626 (2009). · DOI
  56. Kisucka, J. et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc. Natl Acad. Sci. USA 103, 855–860 (2006). · DOI
  57. Manegold, P. C., Hutter, J., Pahernik, S. A., Messmer, K. & Dellian, M. Platelet-endothelial interaction in tumor angiogenesis and microcirculation. Blood 101, 1970–1976 (2003). · DOI
  58. Gasic, G. J., Gasic, T. B. & Stewart, C. C. Antimetastatic effects associated with platelet reduction. Proc. Natl Acad. Sci. USA 61, 46–52 (1968). · DOI · Paper page
  59. Camerer, E. et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104, 397–401 (2004). · DOI · Paper page
  60. Karpatkin, S., Pearlstein, E., Ambrogio, C. & Coller, B. S. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis in vivo. J. Clin. Invest. 81, 1012–1019 (1988). · DOI · Paper page
  61. Sambrano, G. R., Weiss, E. J., Zheng, Y.-W., Huang, W. & Coughlin, S. R. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413, 74–78 (2001). · DOI
  62. Palumbo, J. S. et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96, 3302–3309 (2000). · DOI · Paper page
  63. Versteeg, H. H. et al. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res. 68, 7219–7227 (2008). · DOI
  64. Hu, L., Roth, J. M., Brooks, P., Ibrahim, S. & Karpatkin, S. Twist is required for thrombin-induced tumor angiogenesis and growth. Cancer Res. 68, 4296–4302 (2008). · DOI
  65. Jones, D. S., Wallace, A. C. & Fraser, E. E. Sequence of events in experimental metastases of walker 256 tumor-light, immunofluorescent, and electron microscopic observations. J. Natl. Cancer Inst. 46, 493-& (1971).
  66. Crissman, J. D., Hatfield, J., Schaldenbrand, M., Sloane, B. F. & Honn, K. V. Arrest and extravasation of B16 amelanotic melanoma in murine lungs. A light and electron microscopic study. Lab. Invest. 53, 470–478 (1985).
  67. Sindelar, W. F., Tralka, T. S. & Ketcham, A. S. Electron microscopic observations on formation of pulmonary metastases. J. Surg. Res. 18, 137–161 (1975). · DOI
  68. Borsig, L. et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl Acad. Sci. USA 98, 3352–3357 (2001). · DOI · Paper page
  69. Nieswandt, B., Hafner, M., Echtenacher, B. & Mannel, D. N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59, 1295–1300 (1999).
  70. Malik, G. et al. Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer Res. 70, 4327–4334 (2010). · DOI
  71. Palumbo, J. S. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin. Thromb. Hemost. 34, 154–160 (2008). · DOI
  72. Palumbo, J. S. et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 110, 133–141 (2007). · DOI · Paper page
  73. Wenzel, J., Zeisig, R. & Fichtner, I. Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions. Clin. Exp. Metastasis 27, 25–34 (2010). · DOI
  74. Offermanns, S., Toombs, C. F., Hu, Y.-H. & Simon, M. I. Defective platelet activation in G-α-q-deficient mice. Nature 389, 183–186 (1997). · DOI · Paper page
  75. Palumbo, J. S. & Degen, J. L. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb. Res. 120, S22–S28 (2007). · DOI
  76. Kopp, H. G., Placke, T. & Salih, H. R. Platelet-derived transforming growth factor-β down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 69, 7775–7783 (2009). · DOI · Paper page
  77. Im, J. H. et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 64, 8613–8619 (2004). · DOI · Paper page
  78. Läubli, H. & Borsig, L. Selectins promote tumor metastasis. Semin. Cancer Biol. 20, 169–177 (2010). · DOI · Paper page
  79. Konstantopoulos, K. & Thomas, S. N. Cancer cells in transit: the vascular interactions of tumor cells. Annu. Rev. Biomed. Eng. 11, 177–202 (2009). · DOI
  80. Kim, Y. J., Borsig, L., Han, H. L., Varki, N. M. & Varki, A. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am. J. Pathol. 155, 461–472 (1999). · DOI
  81. Ludwig, R. J. et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 64, 2743–2750 (2004). · DOI
  82. Mousa, S. A. & Petersen, L. J. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb. Haemost. 102, 258–267 (2009). · DOI
  83. Varki, A. P., Varki, N. M. & Borsig, L. Selectins, heparins, and cancer: rationale for clinical trials. Blood 112, 1348–1348 (2008). · DOI
  84. Borsig, L., Wong, R., Hynes, R. O., Varki, N. M. & Varki, A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc. Natl Acad. Sci. USA 99, 2193–2198 (2002). · DOI · Paper page
  85. Laubli, H., Spanaus, K. S. & Borsig, L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood 114, 4583–4591 (2009). · DOI
  86. Alves, C. S., Burdick, M. M., Thomas, S. N., Pawar, P. & Konstantopoulos, K. The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion. Am. J. Physiol. Cell Physiol. 294, C907–C916 (2008). · DOI
  87. McCarty, O. J. T., Mousa, S. A., Bray, P. F. & Konstantopoulos, K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood 96, 1789–1797 (2000). · DOI
  88. Felding-Habermann, B., Habermann, R., Saldivar, E. & Ruggeri, Z. M. Role of β3 integrins in melanoma cell adhesion to activated platelets under flow. J. Biol. Chem. 271, 5892–5900 (1996). · DOI
  89. Amirkhosravi, A. et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb. Haemost. 90, 549–554 (2003). · DOI
  90. Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nature Rev. Cancer 10, 9–22 (2010). · DOI
  91. Bakewell, S. J. et al. Platelet and osteoclast β3 integrins are critical for bone metastasis. Proc. Natl Acad. Sci. USA 100, 14205–14210 (2003). · DOI
  92. Gupta, G. P. & Massague, J. Platelets and metastasis revisited: a novel fatty link. J. Clin. Invest. 114, 1691–1693 (2004). · DOI
  93. Arnaout, M. A., Mahalingam, B. & Xiong, J.-P. Integrin structure, allostery, and bidirectional signaling. Annu. Rev. Cell Dev. Biol. 21, 381–410 (2005). · DOI · Paper page
  94. Rose, D. M., Alon, R. & Ginsberg, M. H. Integrin modulation and signaling in leukocyte adhesion and migration. Immunol. Rev. 218, 126–134 (2007). · DOI · Paper page
  95. Alcaide, P., Auerbach, S. & Luscinskas, F. W. Neutrophil recruitment under shear flow: it's all about endothelial cell rings and gaps. Microcirculation 16, 43–57 (2009). · DOI
  96. Zarbock, A. & Ley, K. Mechanisms and consequences of neutrophil interaction with the endothelium. Am. J. Pathol. 172, 1–7 (2008). · DOI
  97. Barthel, S. R., Johansson, M. W., McNamee, D. M. & Mosher, D. F. Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J. Leukoc. Biol. 83, 1–12 (2008). · DOI
  98. Hyduk, S. J. & Cybulsky, M. I. Role of α4β1 integrins in chemokine-induced monocyte arrest under conditions of shear stress. Microcirculation 16, 17–30 (2009). · DOI
  99. Felding-Habermann, B. et al. Integrin activation controls metastasis in human breast cancer. Proc. Natl Acad. Sci. USA 98, 1853–1858 (2001). · DOI · Paper page
  100. Rolli, M., Fransvea, E., Pilch, J., Saven, A. & Felding-Habermann, B. Activated integrin αvβ3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 9482–9487 (2003). · DOI · Paper page
  101. Felding-Habermann, B. Targeting tumor cell-platelet interaction in breast cancer metastasis. Pathophysiol. Haemost. Thromb. 33, 56–58 (2003). · DOI
  102. Deryugina, E. & Quigley, J. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25, 9–34 (2006). · DOI
  103. Lorger, M., Krueger, J. S., O'Neal, M., Staflin, K. & Felding-Habermann, B. Activation of tumor cell integrin αvβ3 controls angiogenesis and metastatic growth in the brain. Proc. Natl Acad. Sci. USA 106, 10666–10671 (2009). · DOI
  104. Felding-Habermann, B. et al. Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis. Proc. Natl Acad. Sci. USA 101, 17210–17215 (2004). · DOI
  105. Staflin, K. et al. Targeting activated integrin αvβ3 with patient-derived antibodies impacts late-stage multiorgan metastasis. Clin. Exp. Metastasis 27, 217–231 (2010). · DOI
  106. Taverna, D., Crowley, D., Connolly, M., Bronson, R. T. & Hynes, R. O. A direct test of potential roles for β3 and β5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res. 65, 10324–10329 (2005). · DOI
  107. Morimoto, K. et al. Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs. Oncogene 27, 264–273 (2007). · DOI
  108. Jain, S. et al. Platelet glycoprotein Ibα supports experimental lung metastasis. Proc. Natl Acad. Sci. USA 104, 9024–9028 (2007). · DOI
  109. Kitagawa, H. et al. Involvement of platelet membrane glycoprotein Ib and glycoprotein IIb/IIIa complex in thrombin-dependent and -independent platelet aggregations induced by tumor cells. Cancer Res. 49, 537–541 (1989).
  110. Erpenbeck, L., Nieswandt, B., Schon, M., Pozgajova, M. & Schon, M. P. Inhibition of platelet GPIbα and promotion of melanoma metastasis. J. Invest. Dermatol. 130, 576–586 (2009). · DOI
  111. Terraube, V. et al. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J. Thromb. Haemost. 4, 519–526 (2006). · DOI
  112. Terraube, V., Marx, I. & Denis, C. V. Role of von Willebrand factor in tumor metastasis. Thromb. Res. 120, S64–S70 (2007). · DOI
  113. Marsolais, D. & Rosen, H. Chemical modulators of sphingosine 1 -phosphate receptors as barrier-oriented therapeutic molecules. Nature Rev. Drug Discov. 8, 297–307 (2009). · DOI
  114. Yatomi, Y. et al. Sphingosine 1 -phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 96, 3431–3438 (2000). · DOI
  115. Schaphorst, K. L. et al. Role of sphingosine 1 -phosphate in the enhancement of endothelial barrier integrity by platelet-released products. Am. J. Physiol. Lung Cell. Mol. Physiol. 285, L258–L267 (2003). · DOI
  116. Yin, F. & Watsky, M. A. LPA and S1P increase corneal epithelial and endothelial cell transcellular resistance. Invest. Ophthalmol. Vis. Sci. 46, 1927–1933 (2005). · DOI
  117. Sarker, M. H., Hu, D. E. & Fraser, P. A. Regulation of cerebromicrovascular permeability by lysophosphatidic acid. Microcirculation 17, 39–46 (2010). · DOI
  118. Côté, F., Fligny, C., Fromes, Y., Mallet, J. & Vodjdani, G. Recent advances in understanding serotonin regulation of cardiovascular function. Trend in Mol. Med. 10, 232–238 (2004). · DOI
  119. Skolnik, G., Bagge, U., Dhlstrom, A. & Ahlman, H. The importance of 5-HT for tumor cell lodgement in the liver. Int. J. Cancer 33, 519–523 (1984). · DOI
  120. Skolnik, G., Bagge, U., Blomqvist, G., Djarv, L. & Ahlman, H. The role of calcium channels and serotonin (5-HT2) receptors for tumour cell lodegment in the liver. Clin. Exp. Metastasis 7, 169–174 (1989). · DOI
  121. Kuna, P. et al. RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J. Immunol. 149, 636–642 (1992).
  122. Lyman, G. H. et al. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J. Clin. Oncol. 25, 5490–5505 (2007). · DOI · Paper page
  123. Varki, A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 110, 1723–1729 (2007). · DOI · Paper page
  124. Elwood, P. C., Gallagher, A. M., Duthie, G. G., Mur, L. A. J. & Morgan, G. Aspirin, salicylates, and cancer. The Lancet 373, 1301–1309 (2009). · DOI · Paper page
  125. Mackman, N. Triggers, targets and treatments for thrombosis. Nature 451, 914–918 (2008). · DOI · Paper page
  126. Verheul, H. M. W. et al. Platelets take up the monoclonal antibody bevacizumab. Clin. Cancer Res. 13, 5341–5347 (2007). · DOI
  127. Kanter, J., Khan, S. Y., Kelher, M., Gore, L. & Silliman, C. C. Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentrates. Clin. Cancer Res. 14, 3942–3947 (2008). · DOI
  128. Foss, B. & Bruserud, O. Platelet functions and clinical effects in acute myelogenous leukemia. Thromb. Haemost. 99, 27–37 (2008). · DOI
  129. Cervi, D. et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 111, 1201–1207 (2008). · DOI
  130. Klement, G. L. et al. Platelets actively sequester angiogenesis regulators. Blood 113, 2835–2842 (2009). · DOI · Paper page
  131. Borsig, L. The role of platelet activation in tumor metastasis. Expert Rev. Anticancer Ther. 8, 1247–1255 (2008). · DOI
  132. Fang, J. et al. Therapeutic expression of the platelet-specific integrin, αIIbβ3, in a murine model for Glanzmann thrombasthenia. Blood 106, 2671–2679 (2005). · DOI
  133. Freyssinet, J.-M. & Toti, F. Formation of procoagulant microparticles and properties. Thromb. Res. 125, S46–S48 (2010). · DOI
  134. Muralidharan-Chari, V., Clancy, J. W., Sedgwick, A. & D'Souza-Schorey, C. Microvesicles: mediators of extracellular communication during cancer progression. J. Cell Sci. 123, 1603–1611 (2010). · DOI · Paper page
  135. Castellana, D., Toti, F. & Freyssinet, J. M. Membrane microvesicles: macromessengers in cancer disease and progression. Thromb. Res. 125, S84–S88 (2010). · DOI
  136. Baj-Krzyworzeka, M. et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp. Hematol. 30, 450–459 (2002). · DOI · Paper page
  137. Janowska-Wieczorek, A., Marquez-Curtis, L. A., Wysoczynski, M. & Ratajczak, M. Z. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion (Paris). 46, 1199–1209 (2006). · DOI
  138. Janowska-Wieczorek, A. et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int. J. Cancer 113, 752–760 (2005). · DOI · Paper page
  139. Dashevsky, O., Varon, D. & Brill, A. Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int. J. Cancer 124, 1773–1777 (2009). · DOI
  140. Kalinkovich, A. et al. Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells. Cancer Res. 66, 11013–11020 (2006). · DOI
  141. Kim, H. K. et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur. J. Cancer 39, 184–191 (2003). · DOI · Paper page
  142. Helley, D. et al. Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur. Urol. 56, 479–484 (2009). · DOI
  143. Hron, G. et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb. Haemost. 97, 119–123 (2007). · DOI · Paper page
  144. Tesselaar, M. E. et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J. Thromb. Haemost. 5, 520–527 (2007). · DOI · Paper page
  145. Toth, B. et al. Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb. Haemost. 100, 663–669 (2008). · DOI
  146. Thomas, G. M. et al. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J. Exp. Med. 206, 1913–1927 (2009). · DOI · Paper page
  147. Tilley, R. E., Holscher, T., Belani, R., Nieva, J. & Mackman, N. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb. Res. 122, 604–609 (2008). · DOI
  148. Nachman, R. L. & Rafii, S. Platelets, petechiae, and preservation of the vascular wall. N. Engl. J. Med. 359, 1261–1270 (2008).
  149. Von Hundelshausen, P. & Weber, C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ. Res. 100, 27–40 (2007). · DOI · Paper page
  150. Popivanova, B. K. et al. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res. 69, 7884–7892 (2009). · DOI
  151. Jung, D.-W. et al. Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7. Int. J. Cancer 127, 332–344 (2010). · DOI
  152. Keeley, E. C., Mehrad, B., Strieter, R. M., George, F. V. W. & George, K. in Adv. Cancer Res. 91–111 (Academic Press, 2010). · DOI · Paper page
  153. Bajou, K. et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Med. 4, 923–928 (1998). · DOI · Paper page
  154. Geiger, T. R. & Peeper, D. S. Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res. 67, 6221–6229 (2007). · DOI
  155. Bronckaers, A., Gago, F., Balzarini, J. & Liekens, S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med. Res. Rev. 29, 903–953 (2009). · DOI
  156. Ikushima, H. & Miyazono, K. TGFβ signalling: a complex web in cancer progression. Nature Rev. Cancer 10, 415–424 (2010). · DOI · Paper page
  157. Medina, V. A. & Rivera, E. S. Histamine receptors and cancer pharmacology. Br. J. Pharmacol. 161, 755–767 (2010).
  158. Falcon, B. L. et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am. J. Pathol. 175, 2159–2170 (2009). · DOI
  159. Ho, M.-Y. et al. Nucleotide-binding domain of phosphoglycerate kinase 1 reduces tumor growth by suppressing COX-2 expression. Cancer Science 101, 2411–2416 (2010). · DOI
  160. Melnikova, V. & Bar-Eli, M. Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor. Cancer Metastasis Rev. 26, 359–371 (2007). · DOI
  161. Visentin, B. et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9, 225–238 (2006). · DOI · Paper page
  162. David, M. et al. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS ONE 5, e9741 (2010). · DOI
  163. Amirkhosravi, A. et al. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin. Thromb. Hemost. 33, 643–652 (2007). · DOI

Cited by

Metadata

Authors
Gay, L. J., & Felding-Habermann, B.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2011-01-24
Volume
11
Issue
2
Pages
123-134
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
DOI
10.1038/nrc3004
OpenAlex
W1968519475
Cited by
1,645
References
4
FWCI
8.41
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.